Ocugen Wins Bahamas Provisional Approval for OCU400 Gene Therapy
OCGN is trading near its 52-week low of $0.97 (6.2% above the low).
Summary
Ocugen received provisional approval and priority designation from The Bahamas' LARTA Board for OCU400, its modifier gene therapy for retinitis pigmentosa. The company plans to supply OCU400 through an expanded access program and aims to treat the first patient within 90 days after full approval. This is a new regulatory milestone that expands OCU400's global reach beyond the MENA licensing deal signed in July. The news is positive but modest in scale given the small Bahamas market; the real value is as a validation signal for the broader OCU400 program. Watch for full LARTA approval and first patient dosing, which could provide additional momentum.
At the time of this announcement, OCGN was trading at $1.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $339.1M. The 52-week trading range was $0.97 to $2.73. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.